Clinical Study of Weifuchun Treatment on Gastric Cancer

• Status: Completed
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Research purpose To elucidate the effect mechanism and clinical effective of weifuchun in the prevention and treatment of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of weifuchun's treatment on gastric cancer.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ShuGuang Hospital

Criteria

Inclusion Criteria:

1. Patients should be aged between 18 and 70 years old (including 18 and 70 years old) and their gender is not limited.

2. Pathological diagnosis of gastric malignant tumor;

3. The pathological types were adenocarcinoma, tubular adenocarcinoma, mucous adenocarcinoma and sig-ring cell carcinoma (including adenocarcinoma and some sig-ring cell carcinoma);

4. Patients were willing to receive chemotherapy (oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, or Ticeo monotherapy regimen).

5. The patient was willing to receive weifunchun treatment.

Exclusion Criteria:

1. Incomplete pathological diagnostic data;

2. Patients with severe heart, lung, liver, kidney (creatinine greater than the upper limit of the normal range), endocrine, hematopoietic system or psychiatric diseases were considered not suitable for the study group;

3. Pregnant or lactating women, as well as pregnant persons who may not have taken effective contraceptive measures;

4. People who are allergic (allergic to two or more kinds of food, drugs, etc.) or are allergic to known ingredients of the medicine;

5. Patients with other medical conditions that interfere with the trial and are deemed unsuitable for inclusion in the trial by the investigator;

6. Patients enrolled in other clinical trials within the last 1 month.